Article Data

  • Views 434
  • Dowloads 138

Case Reports

Open Access

Malignant mixed mUllerian tumor of the fallopian tube coincident with a primary serous carcinoma of the ovary. Case report

  • L. Nappi1
  • U. Indraccolo1,*,
  • M. Matteo1
  • P. Rosenberg1
  • P. Greco1

1Department Surgical Sciences, Division of Obstetrics and Gynecology, University of Foggia, Italy

DOI: 10.12892/ejgo200706511 Vol.28,Issue 6,November 2007 pp.511-512

Published: 10 November 2007

*Corresponding Author(s): U. Indraccolo E-mail:

Abstract

Malignant mixed müllerian tumors are very rare neoplasms of the fallopian tube, and treatment is not well defined. A case of malignant mixed müllerian tumor of the tube concomitant with a primary serous carcinoma of the ovary is reported. It was unclear if there were two distinct neoplasms in the same patient, or if it was a single tumor with a sarcomatous fallopian conversion of the serous component, as described for some recurrent ovarian carcinomas. Chemotherapy for ovarian carcinoma with intraperitoneal metastasis was performed, with about a three-year interval-free period of disease, as could be expected for ovarian carcinomas at the same stage. Such coexistence of these two tumors does not afford adequate staging of the malignancy. Therapy for the very rare cases similar to the one reported here needs to be improved.

Keywords

Malignant mixed miillerian tumor; Serous ovarian cancer; Therapy

Cite and Share

L. Nappi,U. Indraccolo,M. Matteo,P. Rosenberg,P. Greco. Malignant mixed mUllerian tumor of the fallopian tube coincident with a primary serous carcinoma of the ovary. Case report. European Journal of Gynaecological Oncology. 2007. 28(6);511-512.

References

[1] Gaducci A., Landoni F., Sartori E., Maggino T., Zola P., Gabriele A. et al.: "Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study". Gynecol. Oneal., 2001, 81, 150.

[2] Obermair A., Taylor K.H., Janda M., Nicklin J.L., Crandon A.J., Perrin L.: "Primary fallopian tube carcinoma: the Queensland experience". Int. J. Gynecol. Cancer, 2001, 11, 69.

[3] Butler D.F., Bolton M.E., Spanos W.J. Jr., Day T.G. Jr., Paris K.J., Jose B.O. et al.: "Retrospective analysis of patients with primary fallopian tube carcinoma treated at the University of Louisville". J. Ky Med. Assoc., 1999, 97, 154.

[4] Gagner J.P., Mittal K.: "Malignant mixed Mullerian tumor of the fimbriated end of the fallopian tube: origin as an intraepithelial carcinoma". Gynecol. Oneal., 2005, 97, 219.

[5] Ajithkumar T.V., Minimole A.L., John M.M., Ashokkumar O.S.: "Primary fallopian tube carcinoma". Obstet. Gynecol. Surv., 2005, 60,247.

[6] LimB.J.,凡m J.W., Yang W.I., Cho N.H.: "Malignant mixed mullerian tumor of fallopian tube with multiple distinct heterologous components". Int. J. Gynecol. Cancer, 2004, 14, 690.

[7] Piura B., Rabinovich A., Meirovitz M., Yanai-lnbar I.: "Miillerian adenosarcoma of the uterus: case report and review of literature". Eur. J. Gynaecol. Oneal., 2000, 21, 387.

[8] Benedet J.L., Bender H., Jones 3rd H., Ngan H.Y., Pecorelli S.: "FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers". FIGO Committee on Gynecologic Oncology. Int. J. Gynaecol. Obstet., 2000, 70, 209.

[9] Sreenan J.J., Hart W.R.: "Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis". Am. J. Surg. Pathol., 1995, 19, 666.

[10] Piek J.M., Kenemans P., Verheijen R.H.: "Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause". Am. J. Obstet. Gynecol., 2004, 191, 718.

[11] Callister M., Ramondetta L.M., Jhingran A., Bruke T.W., Eifel P.J.: "Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome". Int. J. Radiat. Oncol. Biol. Phys., 2004, 58, 786.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top